ArticleInternational journal of genomics2026
Multi-Omics Evidence Based on Spatial Transcriptomics Data Reveals the Therapeutic Value of Copper Death Genes in Glioblastoma.
Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-Omics Evidence Based on Spatial Transcriptomics Data Reveals the Therapeutic Value of Copper Death Genes in Glioblastoma.International journal of genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cuprotosis is an emerging form of copper-dependent programmed cell death, while low-grade gliomas (LGGs) represent a common subtype of primary brain tumors. Methods: Datasets from The Cancer Genome Atlas and TargetScan were utilized to identify cuprotosis-related microRNAs (CRMs). Univariate Cox and Lasso regression analyses identified CRMs linked to prognostic outcomes. Prognostic profiles for patients with LGG were constructed using multivariate Cox regression and validated for risk stratification in the CGGA external validation cohort. The study examined clinical features, mutational status, immune cell infiltration, signaling pathways, and immune checkpoint expression across different risk groups. Functional experiments assessed the biological significance of key model genes. Results: Seven CRMs significantly associated with LGG prognosis were identified. The correlation between the CRM signature and poor prognosis in high-risk LGG cases was validated through Kaplan-Meier survival analysis, yielding a one-year area under the curve (AUC) of 0.849, indicating strong predictive accuracy. Risk scores were linked to 1p/19q co-deletion, IDH mutation, and tumor grade, with the model outperforming traditional clinicopathological criteria. Molecular enrichment analyses, including Gene Set Enrichment Analysis (GSEA) and Gene Set Variation Analysis (GSVA), revealed significant associations between high-risk subgroups and pathways related to tumorigenesis and immune dysregulation. Increased tumor mutational burden and elevated IC expression were noted in high-risk cohorts. Furthermore, miR-93-5p was validated as a critical gene, with its disruption leading to significant reductions in GBM cell proliferation, migration, and invasion. Conclusion: The novel CRM signature enhances the prognostic landscape for patients with LGG, offering a new framework for evaluating immunotherapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.